Fasenra Special Precautions

Fasenra should not be used to treat acute asthma exacerbations.
Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.
Abrupt discontinuation of corticosteroids after initiation of Fasenra therapy is not recommended. Reduction in corticosteroid doses, if appropriate, should be gradual and performed under the supervision of a physician.
Hypersensitivity reactions: Acute systemic reactions including anaphylactic reactions and hypersensitivity reactions (e.g. urticaria, papular urticaria, rash) have occurred following administration of Fasenra (see Adverse Reactions). These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e. days).
A history of anaphylaxis unrelated to benralizumab may be a risk factor for anaphylaxis following Fasenra administration (see Contraindications). In line with clinical practice, patients should be monitored for an appropriate time after administration of Fasenra.
In the event of a hypersensitivity reaction, Fasenra should be discontinued permanently and appropriate therapy initiated.
Parasitic (Helminth) Infection: Eosinophils may be involved in the immunological response to some helminth infections. Patients with known helminth infections were excluded from participation in clinical trials. It is unknown if Fasenra may influence a patient's response against helminth infections.
Patients with pre-existing helminth infections should be treated before initiating therapy with Fasenra. If patients become infected, while receiving treatment with Fasenra and do not respond to anti-helminth treatment, treatment with Fasenra should be discontinued until infection resolves.
Effects on ability to drive and use machines: Fasenra has no or negligible influence on the ability to drive and use machines.